INTRODUCTION: Various computational methods for gene expression-based subtyping of highgrade serous (HGS) ovarian cancer have been proposed. This resulted in the identification of molecular subtypes that are based on different datasets and were differentially validated, making it difficult to achieve consensus on which definitions to use in follow-up studies. We assess three major subtype classifiers for their robustness and association to outcome by a meta-analysis of publicly available expression data, and provide a classifier that represents their consensus.
Introduction
Ovarian cancer is a genomically complex disease, for which the accurate characterization of molecular subtypes is difficult but is anticipated to improve treatment and clinical outcome 1 .
Substantial effort has been devoted to characterize molecularly distinct subtypes of high-grade serous (HGS) ovarian cancer ( Table 1) . Initial large scale efforts to classify HGSC of the ovary did not reveal any reproducible subtypes 2 . Tothill et al 3 reported four distinct HGS subtypes: (i) an immunoreactive expression subtype associated with infiltration of immune cells, (ii) a low stromal expression subtype with high levels of circulating CA125, (iii) a poor prognosis subtype displaying strong stromal response, correlating with extensive desmoplasia, and (iv) a mesenchymal subtype with high expression of N/P-cadherins. The Cancer Genome Atlas (TCGA) project also identified four subtypes characterized by (i) chemokine expression in the immunoreactive subtype, (ii) proliferation marker expression in the proliferative subtype, (iii) ovarian tumor marker expression in the differentiated subtype, and (iv) expression of markers suggestive of increased stromal components in the mesenchymal subtype, but did not report differences in patient survival 4 . Further experimental characterization revealed an increased number of samples with infiltrating T lymphocytes for the immunoreactive subtype, whereas desmoplasia, associated with infiltrating stromal cells, was found more often for the mesenchymal subtype 5 . Konecny et al. 6 , independently evaluated the TCGA subtypes and also reported the presence of the four transcriptional subtypes using a de novo clustering and classification method.
However, robustness and clinical relevance of these subtypes remain controversial 7 . The previous subtyping efforts have assessed prognostic significance in different patient cohorts, and have taken different approaches to validate these subtypes in independent datasets. A recent review of ovarian cancer subtyping schemes highlighted the difficulty of comparing results of studies that used different subtyping algorithms, and that better general agreement on how molecular subtypes are defined would allow more widespread use of expression data in clinical trial design. 1 364 Assessing the generalizability of subtyping algorithms is challenging as true subtype classifications remain unknown. This challenge is evident in the lack of published validation of the proposed HGS subtypes. Subsequent efforts have performed de novo clustering of new datasets and noted similarity in the clusters identified, but they have not reported quantitative measures such as classification accuracy or rate of concordance with previously published algorithms. In this article, we address these limitations by re-implementing three major subtyping methods 3, 5, 8 and assess between-classifier concordance and across-dataset robustness. We show that these subtype classifiers yield significant concordance, and are virtually identical for tumors classified with high certainty. Using the core set of tumors concordantly classified by each method, we develop consensusOV, a consensus classifier that has high concordance with the three classifiers, therefore providing a standardized classification scheme for clinical applications.
Materials and Methods

Datasets
Analysis was carried out on datasets from the curatedOvarianData compendium9. Datasets were additionally processed using the MetaGxOvarian package10 (Supplementary Information). Analysis was restricted to datasets featuring microarray-based wholetranscriptome studies of at least 40 patients with late stage, high-grade, primary tumors of serous histology. This resulted in 15 microarray studies, providing data for 1,774 patients ( Supplementary Table 1 ). Duplicated samples identified by the doppelgangR package were removed11. Survival analysis was performed for 13 of these datasets, which included 1,581 patients with annotated time to death or last time of follow-up.
Implementation of Subtype Classifiers
Subtype classifiers were re-implemented in R 12 using original data as described by Konecny 
Survival Analysis
Subtype calls from all included datasets were combined to generate a single Kaplan-Meier plot for each subtyping algorithm (stratified by subtype). Hazard ratios for overall survival between subtypes was estimated by Cox proportional hazards, and statistical significance was assessed by log-rank test, using the survcomp R package 13 . Hazard ratios were calculated using the lowest-risk subtype as the baseline group.
Prediction Strength
Prediction Strength 14 is defined as a measure of the similarity between pairwise comemberships of a validation dataset from class labels assigned by (1) a clustering algorithm and (2) a classification algorithm trained on a training dataset (Supplementary Figure 6 ). The quantity is an established measure of cluster robustness and its interpretation is straightforward: a value of 0 or below indicates poor concordance, and a value of 1 indicates perfect concordance between models specified from training and validation data. Tibshirani and Walther 14 , and subsequent applications of Prediction Strength 15 , have considered a value of at least 0.8 to be an evidence of robust clusters. Prediction Strength was computed as implemented in the genefu Bioconductor package 16 .
The tumors in each dataset were clustered de novo using our reproduced implementations of the algorithms of Konecny, TCGA/Verhaak, and Tothill (Supplemental File, Section 'Reproduction of Subtype Clustering Methods'). Each dataset was also classified using implementation of the originally published subtype classifiers. This produced two sets of subtype labels for each sample in each validation dataset; these labels were used to compute Prediction Strength.
Concordance Analysis
For each pair of classifiers, subtypes were mapped across methods based on concordance, i.e., proportion of patients that were classified as the same (mapped) subtype. Subtype assignment was denoted as concordant only if the pairwise subtype mapping resulted in unique subtypes for each classifier. In other words, if ɸ ij is the mapping of subtypes in classifier i to subtypes in classifier j (for i,j in {1,2,3}), then the following must be satisfied for each subtype : ɸ 12 (ɸ 23 (ɸ 31 (s))) = s. For the purpose of this study, we considered three methods, each of which strictly classifies the patients into distinct subtypes. For datasets resulting in concordant subtype assignments, patients of the same (mapped) subtype across classifiers were assigned to the subtype names proposed by Verhaak et al. 5 . Statistical significance of concordance was assessed by Pearson's Chi-squared test.
Filtering tumors by classification margin
Each subtype classifier outputs for each patient a real-valued score for each subtype. Marginally classifiable tumors were identified based on the difference between the top two subtype scores, denoted as the 'margin' value. Thus, a higher margin indicates a more confident classification.
For each pair of subtype classifiers, classification concordance was assessed on both the full dataset and considering only patients classified with margins above a user-defined cutoff.
Concordance was defined as before (proportion of patients that are classified as the same mapped subtype across methods) to calculate concordance between datasets.
Building a consensus classifier
The consensusOV classifier was implemented using a Random Forest classifier trained on concordant subtypes across multiple datasets. The Random Forest method has previously been used for building a multi-class consensus classifier to resolve inconsistencies among published colorectal cancer subtyping schemes 17 . In order to avoid merging expression values across datasets, binary gene pair vectors were used as feature space, as recently applied for breast cancer subtyping 18, 19 . Since the feature size of this classifier increases quadratically with respect to the size of the original gene set, we used the smallest gene set of the original subtype classifiers (the gene set of Verhaak et al. 5 ), which contains 100 gene symbols. The consensusOV classifier outputs the subtype classification and a real-valued margin score to discriminate between patients that are of well-defined or indeterminate subtype. Similarly to previously published subtype classifiers, a higher margin score indicates higher confidence of classification.
Leave-one-dataset-out cross-validation
Performance of the consensus classifier for identifying concordantly classified subtypes was assessed using leave-one-dataset-out cross-validation 20 . Concordant subtypes were identified to train the Random Forest classifier using 14 of the 15 datasets, and subtype predictions were tested in the remaining left-out dataset. This process was repeated for all 15 datasets. While predicting the samples in any given dataset, the training set was subsetted to contain only the concordant subtypes in other datasets.
Correlation analysis with Histopathology and Tumor Purity
Subtype calls from the Consensus Classifier were analysed for correlation with histopathology and tumor purity in the TCGA dataset. In order to best represent the most confident subtype calls, a default cutoff was used to include only the 25% of patients with the largest classification margins. Available histopathology variables included lymphocyte, monocyte, and neutrophil infiltration. Tumor purity was assessed using the ABSOLUTE algorithm 21 , which estimates purity and ploidy from copy number and SNP allele frequency from SNP genotyping arrays (Synapse dataset syn3242754). Significance of associations were tested by one-way ANOVA for patient age, purity, and immune infiltration.
Research reproducibility
All results are reproducible using R/Bioconductor 22 and knitr 23 
Results
We performed a meta-analysis of three published subtyping algorithms for ovarian cancer 5, 6, 8 and developed a new consensus classifier to identify unambiguously classifiable tumors ( Table   1 ). Each of these algorithms identified four distinct HGS subtypes with specific clinical and tumor pathology characteristics (Figure 1 ). We assessed the algorithms on a compendium of 15 datasets including over 1,700 HGS patients (Supplemental Table 1 ) with respect to concordance, robustness, and association to patient outcome. By modifying individual algorithms to discard tumors of intermediate subtype, we found that concordance between algorithms is greatly improved.
Concordance of published classifiers
We re-implemented three published ovarian subtype classifiers 5, 6, 8 (Table 1) Cramer's V coefficients 24 indicated a strong association between subtypes as identified by the different algorithms (>0.5).
Tumors of intermediate subtype
The Figure 2B ). Three-way concordance followed the same trend with lower overall concordance: a minimum of 23% for the proliferative subtype and maximum of 45% for the immunoreactive subtype when all tumors are classified. Restricting the concordance analysis to the top 50% of tumors by margin value resulted in an increased overlap between 35% (proliferative) and 65% (immunoreactive). At a strict threshold of where only 10% of tumors are classified, 88% of tumors overall are concordantly classified by all three published subtyping algorithms ( Figure 2C ). This large gain in concordance results from large reductions in both singleton calls -tumors assigned to one subtype by one algorithm, but not by the other two algorithms -and in 2-to-1 calls, tumors assigned to one subtype by two algorithms, but not by the third (Figure 2D ). This indicates that tumors distinctly classifiable by a single algorithm are more likely to be concordantly classified by the other algorithms, and conversely, tumors that appear ambiguous to one algorithm are less likely to be classified in the same way by the other algorithms.
Survival Analysis
All proposed subtyping algorithms classified patients into groups that significantly differed in overall survival ( Figure 3A , p < 10 -5 for each subtyping algorithm, log-rank test). Comparing lowrisk to high-risk subtypes for each algorithm, the hazard ratios increase from approximately 1.5
as marginal cases are removed ( Figure 3B ), suggesting that marginal cases may contribute to the intermediate survival profiles between subtypes.
Robustness of the Classifiers
Robust molecular subtyping should be replicable in multiple datasets. We performed de novo clustering in 15 independent ovarian datasets using the authors' original gene lists and clustering methods. We compared these de novo clusters to the labels from our implementation of the published classifiers to assess robustness using the Prediction Strength (PS) statistic 14 .
For PS estimation, we included validation datasets with at least 100 HGS tumors. Overall we observed low robustness for all classifiers, with PS values under 0.6 for the three algorithms across datasets ( Supplementary Figure 7) , none meeting the 0.8 threshold typically indicating robust classes 14, 15 .
To assess whether low confidence predictions are driving the PS estimation, we re-computed the robustness of each algorithm set to classify varying fractions of the tumors with the highest margins. We used the largest dataset available, the TCGA dataset, as the validation set, and varied margin cutoffs of the Tothill and Konecny classifiers to require them to classify between 25% and 100% of the cases. From 10 random clustering runs, we report the median PS for the dataset. Clustering was performed on the full TCGA dataset and tumors of low margin values were removed subsequent to clustering and after the classifier was fully defined, in order to avoid optimistically biasing the apparent strength of clusters. We observed that the robustness of each algorithm is substantially improved by allowing them to refuse to classify ambiguous cases. The Tothill algorithm achieved almost perfect robustness (PS = 0.96) when allowed to leave 75% of cases unclassified (Figure 4 ).
Consensus Classifier
To maximize concordance across classifiers, we developed consensusOV, a consensus subtyping scheme facilitating classification of tumors of well-defined subtypes ( Figure 5 ). This classifier uses binary gene pairs 18, 19 to support application across gene expression platforms.
The consensusOV classifier exhibits overall pairwise concordance of 67 -78% with each of the other three algorithms, when classifying all tumors; and 94% concordance with tumors that are concordantly classified by the other three algorithms ( Figure 5A ). The margins of consensusOV are higher for concordantly classified cases than for non-concordantly classified cases, and this difference in margins is greater than for any of the other three classifiers ( Figure 6A ).
Accordingly, consensusOV was also most effective in identifying concordantly classified cases, although it was similar to the Konecny classifier in this respect (AUC = 0.76, Figure 6B ). As expected, differences in survival of subsets identified by consensusOV are similar to those identified by previous classifiers. The highest risk subtypes are proliferative (HR=1.44, 95% CI:
1.07−1.94) and mesenchymal (HR=1.97, 95% CI: 1.46−2.67) when removing 75% of indeterminate low-margin tumors, with similar hazard ratios for the concordant cases ( Figure   5B ).
Discussion
The existence of four distinct and concordant molecular subtypes of HGOC has been reported
in several studies of large patient cohorts [4] [5] [6] 8 , but also called into question by another effort 2 that could not identify subtypes, and by an independent validation effort that reported only two or three reproducible subtypes 25 . Meanwhile, significant effort is being expended to translate these subtypes to clinical practice, for example to predict response to the angiogenesis inhibitor bevacizumab in the ICON7 trial 26, 27 . This article pursues three major objectives: (1) We find that while the proposed 4-subtype classifications demonstrate significant concordance and association with patient survival, none are robust to re-training in new datasets. By modifying any of these algorithms to refuse to identify tumors of ambiguous subtype, robustness and concordance of subtyping algorithms improve dramatically. We propose a "consensus" classifier for 25% of tumors that can be classified with high confidence regardless of training dataset, although a continuous trade-off exists between classifying more tumors versus having greater confidence in those classified.
Ambiguity in tumor classification might arise from a heterogeneous admixture of different subtypes, or from a more homogeneous composition of indeterminate subtype. This distinction has implications for the therapeutic value of the proposed subtypes. Lohr et al. estimated that 90% of tumors in the TCGA HGS dataset are polyclonal 28 , and clonal spread of HGS ovarian cancer has been directly inferred from single-nucleus sequencing 29 . However, it remains unclear whether multiple clones in a tumor are consistently classifiable to the same subtype. If a tumor consists of multiple clones of different subtypes, then a subtype-specific therapy will likely lead to relapse as other clones survive and continue to grow. If this situation is common, even unambiguously classifiable tumors might be contaminated by small amounts of another subtype that could lead to relapse after subtype-specific therapy. This question could not be resolved by the current datasets, but may eventually be addressed by single-cell RNA sequencing 30 which is expected to further improve precision HGS molecular subtyping.
Several findings stand out in the validation of published subtyping algorithms. First, although previous studies reported inconsistent findings on whether subtypes differ by patient survival, our analysis in independent data showed clear survival differences. The 5-year survival rate for patients with different subtypes ranged from as low as 20% to as high as 50%. Second, published algorithms do not meet previously defined standards of robustness in terms of Prediction Strength, a measure of consistency between subtype classifiers trained in independent datasets. Finally, the concordance of three algorithms, established independently by different research groups from different patient cohorts, is only moderate but can be greatly improved by modifying the original algorithms to allow them to leave ambiguous tumors unclassified. In their original forms, all-way concordance of the four defined classes occurs in 23% to 45% of tumors. As the individual algorithms are modified to leave ambiguous cases unclassified, the minority of tumors remaining can be classified with over 90% concordance between the three algorithms. Unfortunately, these ambiguous cases account for up to 75% of HGSC of the ovary. This has important implications for the clinical application of subtypes in ovarian cancer.
Moving forward, general agreement on how molecular subgroups are defined is expected to facilitate the use of expression data in clinical trial design, thereby improving prognosis as well as treatment benefit 31 . We introduced the subtype classifier consensusOV, which represents the consensus of published HGS subtype classifiers. By training on multiple datasets, using binary (pairwise greater-than or less-than) relationships between pairs of genes, and using a relatively small gene set, consensusOV is designed to be applicable across gene expression platforms and datasets, making it effective for benchmarking and meta-analysis. ; the x-axis shows the percent removed before computing prediction strength. Each algorithm improves in robustness when allowed to leave ambiguous samples, that it is less certain in its classification, unclassified. 
